Isaac Sosa
Internal Medicine · Uvalde, TXNPI 1275558611
Payments from drug & device makers
Across 94 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$427
- Bayer$204
- AstraZeneca$180
- Averitas Pharma Inc.$132
- Amgen$120
- Otsuka America Pharmaceutical, Inc.$77
- plus $542 from 18 others
What the payments were for
- Food & beverage$1,680100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $427 |
| Bayer | 13 | $204 |
| AstraZeneca | 7 | $180 |
| Averitas Pharma Inc. | 6 | $132 |
| Amgen | 6 | $120 |
| Otsuka America Pharmaceutical, Inc. | 5 | $77 |
| Lilly USA, LLC | 4 | $76 |
| Novartis | 3 | $53 |
| Johnson & Johnson | 3 | $43 |
| Boehringer Ingelheim | 3 | $42 |
| GSK | 2 | $42 |
| Exact Sciences | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| UCB, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 2 | $32 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Merck | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Pfizer | 1 | $13 |
| Abbott | 1 | $12 |
How this compares
$1,680 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $174,540 |
| JardianceEmpagliflozin | 139 | $151,613 |
| MounjaroTirzepatide | 135 | $144,394 |
| EliquisApixaban | 170 | $131,369 |
| JanuviaSitagliptin Phosphate | 75 | $100,030 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 93 | $60,156 |
| TradjentaLinagliptin | 57 | $50,061 |
| FarxigaDapagliflozin Propanediol | 58 | $47,472 |
| XifaxanRifaximin | 12 | $39,412 |
| MyrbetriqMirabegron | 61 | $37,826 |
| KerendiaFinerenone | 23 | $31,050 |
| TrulicityDulaglutide | 29 | $30,770 |
| XareltoRivaroxaban | 23 | $28,340 |
| EntrestoSacubitril/Valsartan | 35 | $25,893 |
| RexultiBrexpiprazole | 12 | $22,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta | $42 | $261,830289 claims |
| Lilly USA, LLCMounjaro, Trulicity | $76 | $175,165164 claims |
| Novo NordiskOzempic | $427 | $174,540174 claims |
| PfizerEliquis, Premarin | $13 | $138,326190 claims |
| MerckJanuvia, Janumet | $16 | $120,678108 claims |
| AstraZenecaFarxiga, Symbicort | $180 | $54,03680 claims |
| BayerKerendia | $204 | $31,05023 claims |
| Johnson & JohnsonXarelto | $43 | $28,34023 claims |
| NovartisEntresto | $53 | $25,89335 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $77 | $22,09812 claims |
| GSKTrelegy Ellipta | $42 | $11,93511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Uvalde
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.